GILD pipeline progress across HIV, oncology and inflammation supports growth
Gilead’s diversification has broadened its pipeline across virology, oncology and inflammation, with new launches and promising clinical data in HIV prevention, cell therapy and ADCs. Near-term priorities will shape future growth.